Latest News and Press Releases
Want to stay updated on the latest news?
-
Quadient (Euronext Paris : QDT), un leader des solutions d’entreprise visant à faire de chaque interaction client – via un canal physique ou digital – une expérience riche et personnalisée, annonce la...
-
Quadient (Euronext Paris: QDT), a leader in helping businesses create meaningful customer connections through digital and physical channels, today announced the appointment of Petra Wolf as new Chief...
-
MONTREAL, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Future Electronics today announced the further strengthening of its global executive team. Omar Baig, in addition to holding the positions of President...
-
Press Relations:Sam ConnattyTel.: +44 370 904 3601Email: sam.connatty@capgemini.com Capgemini reinforces its focus on global industries and sustainability services with top leadership appointments ...
-
Press Relations:Victoire GRUXTel.: +33 6 04 52 16 55Email : victoire.grux@capgemini.com Capgemini renforce son approche sectorielle et ses services en matière de développement durable avec l’annonce...
-
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – July 29, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel...
-
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – July 27, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel...
-
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
-
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
-
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – September 30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and...